Equillium, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001), an antibody targeting CD6 for severe autoimmune and inflammatory disorders. It has no product sales or product approved for sale in the United States or Canada.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $3.759 million | $0.663 million |
| General and administrative expense | $2.589 million | $0.374 million |
| Total operating expenses / operating loss | $6.348 million | $1.037 million |
| Net loss | $5.950 million | $1.577 million |
| Net loss per share, basic and diluted | $0.34 | $0.15 |
| Operating cash used | $4.464 million | $0.889 million |
| Cash and cash equivalents, March 31 | $21.394 million | $6.209 million at March 31, 2018 |
| Short-term investments, March 31 | $40.213 million | $37.405 million at December 31, 2018 |
At March 31, 2019, total cash, cash equivalents and short-term investments were $61.6 million; total assets were $62.7 million, total liabilities $3.2 million, and stockholders’ equity $59.5 million. The company reported no interest expense in Q1 2019; convertible promissory notes had converted to equity in October 2018. Interest income was $398,000. No gross margin is applicable because the company had no revenue.
Material changes versus the prior comparable quarter
- Net loss increased to $5.95 million from $1.58 million, principally reflecting higher operating expenses as clinical development and public-company activities expanded.
- R&D expense rose by $3.10 million, mainly from increased clinical development, employee compensation and consulting, and overhead costs.
- G&A expense rose by $2.22 million, driven mainly by compensation and consulting, public-company and travel costs, and legal and professional fees.
- Operating cash use increased by $3.58 million. Investing cash use was $2.65 million, primarily reflecting purchases of short-term investments, partly offset by maturities.
- Cash, cash equivalents and short-term investments declined from $65.9 million at December 31, 2018 to $61.6 million at March 31, 2019.
Outlook, risks and notable items
- Management stated that available cash, cash equivalents and short-term investments were expected to fund planned operations for at least 12 months; the liquidity note says more than a year from the filing date. The company expects losses and negative operating cash flows to continue for several years and will need additional capital to complete development and potentially commercialize itolizumab.
- Clinical plans: the Phase 1b/2 aGVHD trial began in Q1 2019, with Phase 1b topline data expected in Q1 2020. Management planned to begin a Phase 1b proof-of-concept asthma trial in Australia in Q2 2019 and a lupus nephritis Phase 1b proof-of-concept trial in the second half of 2019.
- Itolizumab has FDA Fast Track designation for aGVHD and orphan drug designations for prevention and treatment. These designations do not ensure approval or shorten development timelines.
- A material regulatory uncertainty involves U.S. sanctions/export controls: the antibody sequence has Cuban-origin intellectual property. Equillium relies on an OFAC general license for development activities, while its request for interpretive guidance and, alternatively, specific authorization remained pending. If authorization is unavailable, development and commercialization could be prohibited.
- Equillium’s exclusive U.S. and Canadian license from Biocon entails potential regulatory milestones of up to $30 million, sales milestones of up to $565 million, and tiered royalties. No milestone or royalty payments had been made or received as of the filing.
- The company depends on Biocon for clinical and potential commercial supply, and on third parties for clinical trials. Clinical, regulatory, manufacturing, enrollment, financing, intellectual-property and safety uncertainties could delay or prevent development. Equillium also noted that itolizumab and ALZUMAb are manufactured in different cell lines, so results for ALZUMAb may not predict results for EQ001.
- No legal proceedings or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective as of March 31, 2019 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the planned clinical trials started on schedule and whether aGVHD Phase 1b topline data were delivered on the stated timeline.
- Current cash runway and financing needs relative to trial costs, operating plans and the stated expectation of at least 12 months of funding.
- The status and terms of OFAC guidance or authorization, and the effect of any sanctions decision on EQ001 development.
- Clinical safety and efficacy evidence for EQ001, including how it differs from evidence for Biocon’s ALZUMAb.
- Compliance with Biocon license development obligations and the future impact of milestone payments, royalties and manufacturing dependence.